Press

Press

Good prospects for the future.
You can read about our progress and milestones, about our expansions and our experts, about our engagement and exchanges, in brief: about everything that motivates us.

Press Releases

  1. Heidelberg, September 23, 2022

    EASEE® – World's first minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately

    After seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE®.

    Read more
  2. Heidelberg, April 29, 2022

    Clinical Studies Demonstrate that Patients with Focal Epilepsies Benefit from the Technologically Innovative Therapy EASEE®

    Prof. Andreas Schulze-Bonhage, MD, Head of the Epilepsy Center at the University Hospital Freiburg, who is responsible for the multi-center study on the efficacy of EASEE®, present […]

    Read more
  3. Heidelberg, February 21, 2022

    Minimally Invasive Epilepsy Treatment EASEE® Receives FDA Breakthrough Device Designation

    Heidelberg-based Precisis GmbH has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its EASEE® brain stimulator. FDA’s breakthrough dev […]

    Read more
  4. Heidelberg, October 21, 2021

    Precisis concludes funding round of €20 million for its bioelectric brain stimulation system

    Today, Precisis GmbH, based in Heidelberg, announced that it has successfully concluded a funding round of €20 million with Cochlear Limited. Precisis is a medical technology compa […]

    Read more
Thank you for your interest
We will send you a confirmation email to verify your email address. Please open that email and follow the link it contains to complete registration for the newsletter
News about epilepsy directly to your mailbox
We would be happy to inform you regularly
I am interested in EASEE® and want to be informed about the product by email. I can always revoke consent for future emails.
Privacy
We use cookies and other technologies on our website. Some of them are essential, while others help us to improve this website and your experience with it. For more information about how we use your data, please see our Privacy Policy.